Co‐treatment with an ATR inhibitor results in tumor eradication of MYCN‐driven neuroblastoma and shows no evidence of toxicity to adjacent or highly proliferative tissues, most likely affecting only tumor‐susceptible tissues [34]. The gene discussed is MYCN; the disease is neuroblastoma.